Tg Therapeutics, INC Form 4 insider transactions

Laurence N Charney, a Director of Tg Therapeutics, Inc., reported multiple transactions in common stock on August 6, 2026.

TG Therapeutics Director Sagar Lonial acquired 8,325 Stock Tracking Units on June 11, 2026, which vest on the first anniversary of the grant date.

TG Therapeutics, Inc. reports that Director Daniel Hume acquired 8,325 Stock Tracking Units on June 11, 2026, which vest on the first anniversary of the grant date.

Kenneth Hoberman, a Director at TG Therapeutics, Inc., acquired 8,325 Stock Tracking Units on June 11, 2026, with vesting contingent on continued service.

TG Therapeutics Director Yann Echelard acquired 8,325 Stock Tracking Units on June 11, 2026, as disclosed in a Form 4 filing.

Laurence N. Charney, a Director at TG Therapeutics, Inc., acquired 8,325 Stock Tracking Units on June 11, 2026, with vesting contingent on continued service.

TG Therapeutics Director Laurence N. Charney gifted a total of 43,197 shares of common stock to his children in late January 2026.

TG Therapeutics CEO Michael S. Weiss received a grant of 622,000 performance-based restricted shares, vesting upon outperforming the Nasdaq Biotechnology Index.

TG Therapeutics' CFO, Sean A. Power, was granted 90,000 restricted common shares on January 8, 2026, as part of an equity compensation plan.

TG Therapeutics Director Yann Echelard sold 5,000 shares of common stock at $32.57 per share to cover income tax obligations, retaining 223,816 shares.

TG Therapeutics CEO Michael S. Weiss reported the transfer of 4,668,843 shares of common stock to family trusts for estate planning purposes.

TG Therapeutics Director Sagar Lonial sold 20,852 shares of common stock to cover tax liabilities, retaining 94,061 shares.

TG Therapeutics Director Yann Echelard reported the acquisition of 14,718 restricted shares and the sale of 10,000 shares to cover tax obligations, as detailed in a recent SEC Form 4 filing.

TG Therapeutics, Inc. Director Laurence N. Charney was granted 21,408 shares of restricted common stock, increasing his total beneficial ownership to 222,887 shares.

TG Therapeutics Director Kenneth Hoberman was granted 14,718 shares of restricted common stock on June 12, 2025, increasing his total beneficial ownership to 279,653 shares.

TG Therapeutics, Inc. Director Daniel Hume was granted 14,718 restricted shares of common stock on June 12, 2025, increasing his total beneficial ownership to 192,748 shares.

TG Therapeutics, Inc. director Sagar Lonial was granted 14,718 restricted shares of common stock, vesting in June 2026, as disclosed in a recent SEC Form 4 filing.

Director Daniel Hume reports a transfer of TG Therapeutics stock to a trust for the benefit of his dependents.

Director Laurence N. Charney of TG Therapeutics, Inc. reports a donation of 6,000 common stock shares to a charitable organization.

TG Therapeutics CEO Michael Weiss was granted 750,000 restricted shares that will vest based on the company's total shareholder return compared to the Nasdaq Biotechnology Index over various periods.

Sean Power, CFO of TG Therapeutics, reports acquiring 87,500 shares of common stock through a grant of restricted shares.

TG Therapeutics CFO, Sean A. Power, sold a total of 21,358 shares of common stock to cover tax obligations following the vesting of restricted stock.

A director of TG Therapeutics, Sagar Lonial, sold 5,000 shares of common stock at a price of $30.44 per share.

Director Laurence N. Charney of TG Therapeutics sold 25,000 shares and donated 5,000 shares to a charitable organization.

Director Yann Echelard sold 20,000 shares of TG Therapeutics common stock to cover income tax obligations related to restricted stock vesting.

Director Sagar Lonial reported selling shares to cover tax obligations and receiving a grant of restricted shares.

Director Daniel Hume reports acquisition of 22,250 shares of TG Therapeutics common stock through a restricted share grant.

Director Kenneth Hoberman reports acquiring 22,250 shares of TG Therapeutics common stock through a grant of restricted shares.

Director Yann Echelard reports acquisition of 22,250 shares of TG Therapeutics common stock through a grant of restricted shares.

Laurence N. Charney, a director at TG Therapeutics, acquired 22,250 shares of common stock through a grant on June 19, 2024.